Acumen Stock Analysis

ABOS
 Stock
  

USD 4.63  0.12  2.53%   

The latest spike in Acumen Pharmaceuticals short term price appreciation could raise concerns from retail investors as the firm is trading at a share price of 4.63 on 45,700 in volume. The company directors and management have successfully maneuvered the firm at convenient times to take advantage of all market conditions in August. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.46. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Acumen Pharmaceuticals partners.
Please continue to Trending Equities.
  
The Acumen Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Acumen Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Acumen Stock analysis module also helps to analyze the Acumen Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Acumen Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acumen Pharmaceuticals recorded a loss per share of 9.31. The entity had not issued any dividends in recent years. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on Acumen Pharmaceuticals please contact the company at 434 297 1000 or go to https://acumenpharm.com.

Acumen Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Acumen Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Acumen Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Acumen Pharmaceuticals has very high historical volatility over the last 90 days
Acumen Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 329 K. Net Loss for the year was (82.74 M) with loss before overhead, payroll, taxes, and interest of (12.3 M).
Acumen Pharmaceuticals currently holds about 189.09 M in cash with (23.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 78.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.marketbeat.com: Acumen Pharmaceuticals, Inc. Short Interest Down 32.0 percent in August - MarketBeat

Acumen Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Acumen Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Acumen Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report21st of February 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End21st of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Acumen Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Acumen Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Acumen Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Acumen Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
15th of August 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
1st of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
21st of June 2022
Submission of Matters to a Vote of Security Holders
View
16th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
28th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of February 2022
Unclassified Corporate Event
View
14th of February 2022
Unclassified Corporate Event
View

Acumen Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Acumen Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acumen Pharmaceuticals backward and forwards among themselves. Acumen Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Acumen Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ra Capital Management LpCommon Shares9.8 M45.9 M
Sands Capital Ventures LlcCommon Shares3.4 M16.1 M
Deep Track Capital LpCommon Shares3.1 M14.6 M
Blackrock IncCommon Shares2.7 M12.7 M
Great Point Partners LlcCommon Shares1.5 M7.1 M
Laurion Capital Management LpCommon Shares1.2 M5.7 M
Vanguard Group IncCommon Shares635.8 KM
Note, although Acumen Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Acumen Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 187.38 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acumen Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Acumen Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (11.9) % which means that it has lost $11.9 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (72.81) %, meaning that it created substantial loss on money invested by shareholders. Acumen Pharmaceuticals management efficiency ratios could be used to measure how well acumen pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 25th of September, Acumen Pharmaceuticals shows the Downside Deviation of 5.53, risk adjusted performance of 0.1305, and Mean Deviation of 4.18. Acumen Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Acumen Pharmaceuticals, which can be compared to its rivals. Please confirm Acumen Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Acumen Pharmaceuticals is priced correctly, providing market reflects its regular price of 4.63 per share. Given that Acumen Pharmaceuticals has jensen alpha of 0.6283, we suggest you to validate Acumen Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Acumen Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Acumen Pharmaceuticals highest and lowest values attained during the given period.
.

Acumen Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acumen Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acumen Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acumen Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Acumen Pharmaceuticals Predictive Daily Indicators

Acumen Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acumen Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Acumen Pharmaceuticals Forecast Models

Acumen Pharmaceuticals time-series forecasting models is one of many Acumen Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acumen Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Acumen Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Acumen Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acumen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Acumen Pharmaceuticals. By using and applying Acumen Stock analysis, traders can create a robust methodology for identifying Acumen entry and exit points for their positions.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Current Acumen Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acumen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acumen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
23.33Buy3Odds
Acumen Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Acumen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acumen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acumen Pharmaceuticals, talking to its executives and customers, or listening to Acumen conference calls.
Acumen Analyst Advice Details

Acumen Stock Analysis Indicators

Acumen Pharmaceuticals stock analysis indicators help investors evaluate how Acumen Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acumen Pharmaceuticals shares will generate the highest return on investment. By understating and applying Acumen Pharmaceuticals stock analysis, traders can identify Acumen Pharmaceuticals position entry and exit signals to maximize returns.
Shares Percent Shares Out2.34%
Quick Ratio48.08
Fifty Two Week Low3.0200
Short Percent Of Float3.12%
Forward Price Earnings-3.92
Float Shares14.19M
Fifty Two Week High16.5000
Shares Short Prior Month2.02M
Average Daily Volume Last 10 Day57.54k
Average Daily Volume In Three Month114.16k
Fifty Day Average5.5702
Two Hundred Day Average5.0943
Please continue to Trending Equities. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for analysis

When running Acumen Pharmaceuticals price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Acumen Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.